How has Iovance Biotherapeutics, Inc.'s net investment in lease changed year-over-year?

Iovance Biotherapeutics, Inc.'s net investment in lease decreased by 12.8% year-over-year, from $50.9M to $44.38M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s net investment in lease?

Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s net investment in lease has grown at a -3.5% compound annual growth rate (CAGR), from $54.76M to $45.9M.

Iovance Biotherapeutics, Inc. IOVA Net Investment in Lease

Net Investment in Lease at other companies

ImmunomeIMNM

——

Nuvation BioNUVB

——

ImmunityBio, Inc.IBRX

——

Viridian Therapeutics, Inc.VRDN

——

Protagonist TherapeuticsPTGX

——

Summit TherapeuticsSMMT

——

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s net investment in lease?: Iovance Biotherapeutics, Inc. (IOVA) reported net investment in lease of $44.38M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s net investment in lease changed year-over-year?: Iovance Biotherapeutics, Inc.'s net investment in lease decreased by 12.8% year-over-year, from $50.9M to $44.38M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s net investment in lease?: Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s net investment in lease has grown at a -3.5% compound annual growth rate (CAGR), from $54.76M to $45.9M.